Literature DB >> 8686534

Complications after multidisciplinary treatment of cerebral arteriovenous malformations.

R Deruty1, I Pelissou-Guyotat, D Amat, C Mottolese, Y Bascoulergue, F Turjman, J P Gerard.   

Abstract

PATIENTS AND TECHNIQUES: A series of 67 patients treated for cerebral AVMs with a multidisciplinary approach is reported, with special attention for the complications due to treatment. The malformations were classified after the Spetzler Grading Scale, with 67% low-grade and 33% high-grade AVMs. Three modes of treatment were used: surgical resection, endovascular embolization, and radiosurgery (linear accelerator technique). The actual treatment was: resection alone (25% of cases), embolization plus resection (24%), embolization alone (21%), and radiosurgery (30%), either alone or after embolization or surgery. The following eradication rates were obtained: overall 80%, after resection (with or without embolization) 91%, after embolization alone 13%, after radiosurgery 87%. CLINICAL OUTCOME: The outcome was evaluated in terms of deterioration due to treatment. A deterioration after treatment occurred in 19 patients (28%), and was a minor deterioration (19%), a neurological deficit (4%), or death (4%). As far as the mode of treatment is concerned, surgical resection was responsible for deterioration (minor) in 17% of all cases operated upon. Radiosurgery was followed by a minor deterioration in 10% of irradiated cases. Embolization gave a complication in 25% of all embolized cases (minor or neurological deficit, or death). The mechanism of the complications was: resection or manipulation of an eloquent area during surgery, radionecrosis after radiosurgery, ischaemia and haemorrhage (50% each) following embolization. In most cases of haemorrhage due to embolization, occlusion of the main venous drainage could be demonstrated. DISCUSSION: The haemodynamic disturbances to AVMs and to their treatment are reviewed in the literature. The main haemodynamic mechanisms admitted at the beginning of a complication after treatment of cerebral AVMs are the normal perfusion pressure breakthrough syndrome, the disturbances of the venous drainage (venous overload or occlusive hyperaemia), and the retrograde thrombosis of the feeding arteries.
CONCLUSIONS: According the authors' experience, the emphasis of treatment for cerebral AVMs has now shifted from surgical resection to endovascular embolization. One of the explanations is that endovascular techniques are now employed in the most difficult cases (high grade AVMs). As severe complications of endovascular embolization may also occur for low-grade malformations, the question arises whether surgery or radiosurgery should not be used first for this low-grade group even if embolization is feasible.

Entities:  

Mesh:

Year:  1996        PMID: 8686534     DOI: 10.1007/bf01411350

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  43 in total

1.  A new haemodynamic factor in cerebral AVM. Aspiration from the venous system demonstrated in two cases of pedonculo-Galen AVM successfully cured by occlusion of the superior longitudinal sinus.

Authors:  B Pertuiset; D Ancri; M Mahdi; H Nakano; F Arthuis; E Bagnat-Guilly
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

2.  Hemodynamics of arteriovenous malformations.

Authors:  R Leblanc; J R Little
Journal:  Clin Neurosurg       Date:  1990

3.  A study of the reactivity of feeding vessels to arteriovenous malformations: correlation with clinical outcome.

Authors:  K Muraszko; H H Wang; G Pelton; B M Stein
Journal:  Neurosurgery       Date:  1990-02       Impact factor: 4.654

4.  Retrograde thrombosis of feeding arteries after removal of arteriovenous malformations.

Authors:  Y Miyasaka; K Yada; T Ohwada; T Kitahara; M Endoh; M Saito; A Kurata; H Ohtaka
Journal:  J Neurosurg       Date:  1990-04       Impact factor: 5.115

5.  Relationship of perfusion pressure and size to risk of hemorrhage from arteriovenous malformations.

Authors:  R F Spetzler; R W Hargraves; P W McCormick; J M Zabramski; R A Flom; R S Zimmerman
Journal:  J Neurosurg       Date:  1992-06       Impact factor: 5.115

6.  [Instantaneous measurement of blood flow velocity in internal carotid arteries by pulsed Doppler in cerebral arteriovenous malformations].

Authors:  D Ancri; B Pertuiset
Journal:  Neurochirurgie       Date:  1985       Impact factor: 1.553

7.  Arteriovenous malformation hemodynamics: a transcranial Doppler study.

Authors:  I F Manchola; A A De Salles; T K Foo; R H Ackerman; G T Candia; R N Kjellberg
Journal:  Neurosurgery       Date:  1993-10       Impact factor: 4.654

8.  Normal perfusion pressure breakthrough theory.

Authors:  R F Spetzler; C B Wilson; P Weinstein; M Mehdorn; J Townsend; D Telles
Journal:  Clin Neurosurg       Date:  1978

9.  The paradoxical blood pressure-flow relationship in the brain with an arteriovenous malformation.

Authors:  M Taneda; T Hayakawa
Journal:  Surg Neurol       Date:  1993-11

10.  Successful treatment of the normal perfusion pressure breakthrough syndrome.

Authors:  A L Day; W A Friedman; G W Sypert; J P Mickle
Journal:  Neurosurgery       Date:  1982-11       Impact factor: 4.654

View more
  14 in total

Review 1.  Endovascular management of arteriovenous malformations of the brain.

Authors:  Charles A Bruno; Philip M Meyers
Journal:  Interv Neurol       Date:  2013-09

2.  Angioarchitectural characteristics associated with complications of embolization in supratentorial brain arteriovenous malformation.

Authors:  J Pan; H He; L Feng; F Viñuela; Z Wu; R Zhan
Journal:  AJNR Am J Neuroradiol       Date:  2013-07-25       Impact factor: 3.825

3.  A nonadhesive liquid embolic agent of ethylene vinyl alcohol copolymer and ethanol mixture for cerebral arteriovenous malformations. Clinical experience.

Authors:  J I Hamada; Y Kai; T Mizuno; M Morioka; K Kazekawa; H Iwata; Y Ushio
Journal:  Interv Neuroradiol       Date:  2008-06-09       Impact factor: 1.610

4.  Endovascular treatment of cerebral arteriovenous malformations with emphasis on the curative role of embolisation.

Authors:  A Valavanis; A Pangalu; M Tanaka
Journal:  Interv Neuroradiol       Date:  2005-10-27       Impact factor: 1.610

5.  Can induction of systemic hypotension help prevent nidus rupture complicating arteriovenous malformation embolization?: analysis of underlying mechanism achieved using a theoretical model.

Authors:  T F Massoud; G J Hademenos; W L Young; E Gao; J Pile-Spellman
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

6.  Feasibility of the superselective test with propofol for determining eloquent brain regions in the endovascular treatment of arteriovenous malformations.

Authors:  José A Jordán González; Juan Carlos Llibre Guerra; José A Prince López; Frank Vázquez Luna; Raúl Marino Rodríguez Ramos; José Carlos Ugarte Suárez
Journal:  Interv Neuroradiol       Date:  2013-09-26       Impact factor: 1.610

7.  Microsurgery for cerebral arteriovenous malformation management: a Siberian experience.

Authors:  Alexei L Krivoshapkin; Evstafy G Melidy
Journal:  Neurosurg Rev       Date:  2005-02-03       Impact factor: 3.042

8.  Adjuvant embolization with N-butyl cyanoacrylate in the treatment of cerebral arteriovenous malformations: outcomes, complications, and predictors of neurologic deficits.

Authors:  Robert M Starke; Ricardo J Komotar; Marc L Otten; David K Hahn; Laura E Fischer; Brian Y Hwang; Matthew C Garrett; Robert R Sciacca; Michael B Sisti; Robert A Solomon; Sean D Lavine; E Sander Connolly; Philip M Meyers
Journal:  Stroke       Date:  2009-05-28       Impact factor: 7.914

9.  Effect of glacial acetic acid and ethiodized oil concentration on embolization with N-butyl 2-cyanoacrylate: an in vivo investigation.

Authors:  Matthew J Gounis; Baruch B Lieber; Ajay K Wakhloo; Ralf Siekmann; L N Hopkins
Journal:  AJNR Am J Neuroradiol       Date:  2002 Jun-Jul       Impact factor: 3.825

10.  Embolization and radiosurgery for arteriovenous malformations.

Authors:  Andres R Plasencia; Alejandro Santillan
Journal:  Surg Neurol Int       Date:  2012-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.